DCE-MRI PET Bevacizumab Study in Rectal Cancer

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT01426074
Phase
PHASE2
Status
Withdrawn

Conditions

  • Rectal Cancer Patients

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will determine the following: the response rate (including pathological CR rate), TTP, and complications of treatment in patients with rectal cancer treated with FOLFOX bevacizumab, the alteration of tumor blood flow (assessed by DCE-MRI as percentage change in Ktrans) after 1 cycle of bevacizumab therapy compared to baseline value in patients treated with FOLFOX alone and those treated with bevacizumab at 5 mg/kg., the degree of hypoxis (measured by tumor uptake of the 2-nitroimidazole EF5) induced by bevacizumab treatment and its relationship to changes in tumor blood flow, and the degree of apoptosis (measured by tumor uptake of di-annexin V) induced by bevacizumab treatment and its relationship to changes in tumor blood flow.

Key Dates

First listed
Aug 31, 2011
Start date
Aug 31, 2011
Status verified
Aug 2018
Primary completion
Jun 11, 2014
Completion
Jun 11, 2014

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Primary Outcome Measure

Pathologic Complete Response (pCR)

Related Studies